Press release
Malmö, September 20, 2018
Acarix CADScor®System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users.
Acarix AB (publ) ("Acarix"), today reported positive feedback from German users of its handheld CADScor®System for ruling out CAD. Germany is an important market and Acarix offers a reimbursement code for private patients and is continuing the reimbursement process for statutory health insurance patients with the aim of providing physicians with more opportunities to use the CADScor®System for their patients.
Dr. Klaus Remde of the Internistische Privatpraxis in Heidelberg, one of the early adopters says, "We have used theCADScor®System with more than 70 patients over the last few months, and we have noted tremendous added value in terms of decision making at an early stage of the diagnostic pathway and in our ability to determine next steps for patients with potential CAD. With the support of the CADScor®System, we can ensure efficient use of our resources for each individual patient."
"We are delighted with this positive feedback from our German customers,"says Per Persson, Chief Commercial Officer at Acarix. "This is the result of a sustained effort in what is a demanding market. First adopters, such as Dr. Remde, have been key to our success and we are now noting increasing interest in theCADScor®System across the German and Austrian markets."
The CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flows and myocardial movements together with advanced algorithms in a portable device, to provide a patient-specific score enabling the non-invasive assessment of the risk of CAD in less than 8 minutes. This provides physicians with a rapid, front line tool for early assessment before moving on to more expensive and invasive methods.
Contacts:
Christian Lindholm, interim CEO, E-mail: secli@acarix.com, Phone: +46 705 118 333
Notes to editors:
Acarix, CADScor®System and cardiac sound measurement
Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix's CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD score, on the device screen. Readings are obtained in less than 8 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful and invasive diagnostic procedures.
See more at www.acarix.com. Press photos: http://www.acarix.com/about-us/press-downloads/press-photos/.
Press release Germany ENG Final_ENG
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire
